The IL-1 b Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

rom INSERM U1096, Rouen, France; Normandy University, IRIB, Rouen, France; Unité édecine et Pharmacie, Rouen University, Rouen, France; Plateau d’Imagerie CardioThor ouen, France; Bruker Biospin MRI GMBH, Ettlingen, Germany; Institut de Recherches rance; and the Pharmacology Department, Centre Hospitalier Universitaire de Reims, Reims y Servier France and by European Union and Région Normandie. The European Union is asso uropean Regional Development Fund (ERDF). Drs. Bolduc, Bouly, and Roussel are employ ecipient of an Erasmus grant. All other authors have reported that they have no relationshi aper to disclose. Antonio Abbate, MD, PhD, served as Guest Editor for this paper.

[1]  A. Matsumori,et al.  Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. , 2001, Journal of the American College of Cardiology.

[2]  G. Biondi-Zoccai,et al.  Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction , 2008, Circulation.

[3]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[4]  G. Habermehl,et al.  Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. , 1990, Kidney international.

[5]  S. Carbone,et al.  Interleukin-1&bgr; Blockade Improves Left Ventricular Systolic/Diastolic Function and Restores Contractility Reserve in Severe Ischemic Cardiomyopathy in the Mouse , 2014, Journal of cardiovascular pharmacology.

[6]  S. Wesselingh,et al.  Cytokine mRNA expression in postischemic/reperfused myocardium. , 1995, The American journal of pathology.

[7]  D. Mann,et al.  Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. , 2004, Cardiovascular research.

[8]  S. Harrison,et al.  TNF-α and IL-1β increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes , 2010, Cell calcium.

[9]  A. Shah,et al.  Role of nitric oxide in posthypoxic contractile dysfunction of diabetic cardiomyopathy , 2003, European journal of heart failure.

[10]  F. Dominici,et al.  Antifibrotic Effects of Pioglitazone at Low Doses on the Diabetic Rat Kidney Are Associated with the Improvement of Markers of Cell Turnover, Tubular and Endothelial Integrity, and Angiogenesis , 2010, Kidney and Blood Pressure Research.

[11]  B. V. Van Tassell,et al.  Targeting interleukin-1 in heart disease. , 2013, Circulation.

[12]  N. Frangogiannis,et al.  The role of IL-1 in the pathogenesis of heart disease , 2009, Archivum Immunologiae et Therapiae Experimentalis.

[13]  G. Biondi-Zoccai,et al.  Anakinra in Experimental Acute Myocardial Infarction—Does Dosage or Duration of Treatment Matter? , 2009, Cardiovascular Drugs and Therapy.

[14]  S. Lancel,et al.  Redox-mediated reciprocal regulation of SERCA and Na+-Ca2+ exchanger contributes to sarcoplasmic reticulum Ca2+ depletion in cardiac myocytes. , 2010, Free radical biology & medicine.

[15]  W. Paulus,et al.  The failing diabetic heart: Focus on diastolic left ventricular dysfunction , 2009, Current Diabetes Reports.

[16]  Y. Yazaki,et al.  Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. , 1990, Biochemical and biophysical research communications.

[17]  G. Biondi-Zoccai,et al.  Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). , 2015, The American journal of cardiology.

[18]  R. Arena,et al.  Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure , 2012, PloS one.

[19]  J. Loscalzo,et al.  Glucose‐6‐Phosphate Dehydrogenase Modulates Cytosolic Redox Status and Contractile Phenotype in Adult Cardiomyocytes , 2003, Circulation research.

[20]  F. Lallemand,et al.  Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.

[21]  Yao Sun,et al.  Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats , 2008, Molecular and Cellular Biochemistry.

[22]  P. Larsen,et al.  Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity , 2010, The Journal of Biological Chemistry.

[23]  F. Lallemand,et al.  Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure , 2004, Circulation.

[24]  D. Harrison,et al.  Uncoupled Cardiac Nitric Oxide Synthase Mediates Diastolic Dysfunction , 2010, Circulation.

[25]  M. Netea,et al.  One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. , 2015, Clinical immunology.

[26]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[27]  M. Pfeffer,et al.  Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. , 1985, Circulation.

[28]  P. Galuppo,et al.  Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction , 2008, Circulation.

[29]  P. Kaufmann,et al.  Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. , 1999, Circulation.

[30]  R. Hajjar,et al.  Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy , 2012, Nature Reviews Cardiology.

[31]  OrianneHenri,et al.  Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction , 2016 .

[32]  B. V. Van Tassell,et al.  Interleukin‐1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse , 2010, European journal of heart failure.

[33]  P. Rösen,et al.  Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose. , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[34]  M. Gómez-Lechón,et al.  Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. , 1995, The American journal of physiology.

[35]  H. Otani.  The role of nitric oxide in myocardial repair and remodeling. , 2009, Antioxidants & redox signaling.

[36]  V. Richard,et al.  Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. , 1994, Circulation.

[37]  A. Topaloğlu,et al.  Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings. , 2003, Journal of pediatric endocrinology & metabolism : JPEM.

[38]  N. Khaper,et al.  Inflammatory cytokines and postmyocardial infarction remodeling. , 2004, Circulation research.

[39]  D. Brutsaert,et al.  Intracavitary ultrasound impairs left ventricular performance: presumed role of endocardial endothelium. , 1992, The American journal of physiology.

[40]  R. Henkelman,et al.  Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice , 2010, Diabetes.

[41]  John Corbin,et al.  XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases , 2011, mAbs.

[42]  Anindita Das,et al.  Interleukin-1 Trap Attenuates Cardiac Remodeling After Experimental Acute Myocardial Infarction in Mice , 2010, Journal of cardiovascular pharmacology.

[43]  G. Biondi-Zoccai,et al.  Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.

[44]  B. V. Van Tassell,et al.  Interleukin-1β induces a reversible cardiomyopathy in the mouse , 2013, Inflammation Research.

[45]  M. Cleman,et al.  Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. , 2014, JACC. Heart failure.

[46]  H. Drexler,et al.  Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. , 1994, Circulation.

[47]  P. Mulder,et al.  Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. , 2008, European heart journal.

[48]  F. Recchia,et al.  Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. , 2009, American journal of physiology. Heart and circulatory physiology.

[49]  J. Bronzwaer,et al.  Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension , 2008, Circulation.

[50]  G. Schreiner,et al.  Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Edwin Wu,et al.  Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. , 2016, Journal of the American College of Cardiology.

[52]  G. Biondi-Zoccai,et al.  Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. , 2013, The American journal of cardiology.

[53]  W. Colucci,et al.  Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. , 2001, American journal of physiology. Cell physiology.

[54]  S. Epstein,et al.  Intravenously Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy , 2017, Circulation research.